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Pramipexole, the most commonly prescribed dopamine agonist worldwide, meanwhile serves as a reference substance for
evaluation of new drugs. Based on numerous clinical data and vast experiences, eﬃcacy and safety proﬁles of this non-ergoline
dopamine agonist are well characterized. Since October 2009, an extended-release formulation of pramipexole has been available
for symptomatic treatment of Parkinson’s disease. Pramipexole administration can be cut down from three times to once a day
due to the newly developed extended-release formulation. This is considerable progress in regard to minimizing pill burden
and enhancing compliance. Moreover, the 24h continuous drug release of the once-daily extended-release formulation results
in fewer ﬂuctuations in plasma concentrations over time compared to immediate-release pramipexole, given three times daily.
The present study summarizes pharmacokinetics and all essential pharmacological and clinical characteristics of the extended-
release formulation. In addition, it provides all study data, available so far, with regard to transition and de-novo administration
of extended-release formulation for patients with Parkinson’s disease. It further compares eﬃcacy and safety data of immediate-
release pramipexole with the extended-release formulation of pramipexole.
1.Introduction
Parkinson’s disease is a chronic neurodegenerative illness
that requires regular medication unlimited in time. Parkin-
sonian patients will comply much more readily to sim-
ple therapeutic regimens with fewer applications than to
treatments with more frequent drug administration [1].
Pharmacologic developments of improved dopaminergic
medication—which has been established as an eﬃcient way
of controlling motor symptoms in idiopathic Parkinson’s
syndrome—accordingly focus on the reduction of the tablet
load and on simple treatment options that are convenient for
the patient. The objective is to enhance better compliance
and consecutively optimum long-term outcomes by creating
a more acceptable form of application—that is, an extended-
release preparation that has to be taken only once a day.
A prolonged-action drug permits the steady release of
the active ingredient over 24 hours preventing the active
concentration from continuously surging on and surging
oﬀ as commonly encountered with multiple applications of
the substance. An unvarying, eﬃcient level by continuous
release over 24 hours will help avoid losses during the course
of the day. This is nurtured by the hope for better control
of motor symptoms during the day and for less nocturnal
and matutinal complaints, akinesia for instance, aside from
late motor complications in the long run. At the same time,
undesired eﬀects might be abated since peak concentrations
no longer occur.
Pramipexole, the dopamine agonist that had been a non-
depotformulasofar,whichpatientshadtotaketid(3x)daily,
could be turned into a controlled-release drug to be admin-
istered once daily. This paper gives an overview regarding2 Parkinson’s Disease
the development and pharmacology of the extended-release
form of pramipexole, and it summarizes the available clinical
data on depot pramipexole in the treatment of early and
advanced Parkinson’s disease.
2. Pharmacology andMechanismof Action
Pramipexole (brand name MIRAPEX, SIFROL) is a selec-
tive dopamine D2 receptor agonist, approved since 1998.
Pramipexole is indicated for the symptomatic treatment of
Parkinson’sdisease(idiopathicParkinson’ssyndrome),either
alone (without levodopa) or in combination with levodopa,
that is, during the entire progress of disease up to the
advanced stage.
Pramipexole is a full nonergoline dopamine agonist
with selective aﬃnity for dopamine receptors of the D2
subfamily. This substance shows a 7- to 10-fold higher
aﬃnity to D3 (Ki = 0.5nM) than to D2 receptors (Ki =
3.9nM). Pramipexole acts on presynaptic as well as on post-
synaptic receptors [2, 3]. In intact dopaminergic systems,
though, the eﬀects of pramipexole are primarily stirred via
presynaptic autoreceptors of the D3 and D2 type, thereby
reducing the synthesis and synaptic release of dopamine.
Eﬀects on postsynaptic receptors are only observed at
higher doses, and they are marked by prolonged latency
periods. With reduced dopamine release due to loss or
damageofthepresynaptictermini,however,thepostsynaptic
D2 and D3 receptors are additionally and immediately
stimulated.
Pramipexole mediates its therapeutic action on motor
deﬁcits in Parkinson’s disease via the postsynaptic D2 and D3
receptors of the direct and indirect striatofugal nerve tracts.
Here, pramipexole corrects the increased inhibitory impact
of the direct pathway on motor activity by enhancing the
direct transmission (through D3 receptors) and reducing the
indirect transmission (through D2 receptors) [4].
3.ObjectivesinDeveloping
the Controlled-Release Form
Until 2009, immediate release pramipexole tablets had been
oﬀered at a dosage of 0.125mg, 0.25mg, 0.5mg, and 1.0mg
salt (equivalent to 0.18, 0.35, and 0.7mg base). Owing
to their half-life of 8–12 hours, these immediate-release
pramipexole tablets are taken tid in 3 equal doses to ensure
the daily requirement. It has been an ardent desire of
patients, doctors, care persons/family members to reduce
the number of applications to a once-daily regimen. Other
goals in the development of a controlled-release pramipexole
formula were the simple 1:1 conversion from immediate-
release pramipexole to extended-release pramipexole tablets
overnight, a similar or improved peak/trough ﬂuctuation,
comparable plasma concentrations and comparable eﬃ-
cacy between the two formulas. Another signiﬁcant objec-
tive was preventing the sudden and uncontrolled release
of the active agent by all means (= “dose dumping”)
under fasting conditions, after the ingestion of food and
also of alcohol, which could lead to increased adverse
eﬀects.
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Figure 1: In vitro dissolution proﬁle of the best formulation
prototypes (Boehringer Ingelheim).
The drug substance pramipexole possesses numerous
properties that encumbered development of a prolonged-
release formula [5]. Due to its excellent eﬃcacy, pramipexole
is very low dosed, which demands a particular standard
for the accuracy of dosage. Pramipexole is, moreover, well
soluble in water and physiologic ﬂuids such as gastric and
enteric juice. This is ideal grounds for immediate-release
pramipexole formulas but a great challenge in terms of
deliberately delayed release. Immediate-release pramipexole
tablets are oﬀered in many potencies to titrate the patients to
the appropriate right dose. One therefore tried to develop a
greatnumberofdepotpramipexoledosageswithanidentical
release of the active agent and dose-linear bioavailability.
4. GalenicsandAbsorption Proﬁle
S e v e r a lh u n d r e d so fp h a r m a c e u t i c a lf o r m u l a sw e r ed e v e l -
oped in view of these diﬃcult challenges. There are so-called
in vitro dissolution tests to test the behavior of prototypes.
As depicted in Figure 1, seven formulas ﬁve pellet formulas
and two so-called matrix tablets among them presented with
a highly promising in vitro release proﬁle.
All of these seven prototypes were also tested in a
clinical phase I study. In a crossover study with in healthy
male subjects [6], the pharmacokinetic properties were
investigated in the steady state. An optimal formula for
further clinical development was supposed to be identiﬁed
based on the following target criteria:
(1) a maximum plasma concentration (Cmax, ss), in
the steady state (day 4 of each extended-release
pramipexole therapy), that does not exceed the one
obtained after immediate-release pramipexole t.i.d.,
and a minimum plasma concentration (Cmin, ss)n o t
less than the one observed after the immediate-
release formula applied t.i.d,Parkinson’s Disease 3
(2) a peak/trough ﬂuctuation (PTF) over 24 hours that
is smaller than or comparable to the one following
immediate-release pramipexole,
(3) a bioavailability not less than ≥75% in the steady
state that compares with the immediate-release for-
mula,
(4) no incidence of irregular release (“dose-dumping”
deﬁned as a not more than 80% dose absorption
within 4 hours after application).
One matrix tablet (formula 2, Figure 1)m e ta l lo f
the above criteria and was chosen for further clinical
development. It consists of an innovative hydrogel for-
mula. With this kind of tablet, the drug substance is
homogeneously embedded in a polymeric matrix. The slow
down (= extended release) of the agent is accomplished by
combining three polymers hypromellose, corn starch, and
carbomer. The interaction of these three polymers warrants
the uniform and long-lasting release of the agent over 24
hours.Uponcontactwithdigestivejuices,thedrugsubstance
is ﬁrst dissolved at the surface. The matrix then starts
swelling, forming a viscous jelly that releases pramipexole
consistently over 24 hours. Because of pramipexole’s good
solubility independent from pH-value, the drug substance
is dissolved from the matrix also in deeper intestinal
segments and is ready for absorption. We do not found
a relevant inﬂuence on gastric emptying or intestinal
motility.
In vitro tests showed that the consumption of alcohol
does not impair the matrix structure. A sudden “dose
dumping” can thus be excluded.
5.Pharmacokinetics
A level A in vitro/in vivo correlation (IVIVC) with the
chosen formula was established in the course that was able to
predict a complete plasma concentration proﬁle in humans
by in vitro solubility charts [7] with adequate precision. This
IVIVC also showed that pramipexole of the extended-release
formulawassteadilyabsorbedallthroughtheentireintestine
including the colon. The variability among other individuals
in this process was rather low and not inﬂuenced by other
factors food for instance (Table 1).
In a relative study on bioavailability, pharmacokinetic
parameters were compared after the highest daily dose
of 3.15mg (base, equivalent to 4.5mg salt), administered
as extended-release pramipexole once daily (q.d.) or as
immediate-release pramipexole, 3x daily (t.i.d.) 1.05mg
base. The impact of food on the pharmacokinetics of
extended-release pramipexole was additionally studied. The
results were indicative of equivalent pramipexole plasma
concentrations in the time span deﬁned as surface on
the chart (AUC0–24,ss). There were no further relevant
diﬀerences in the maximum (Cmax,ss) and minimum con-
centrations (Cpre,ss-measured right before the ﬁrst morn-
ing dose). No signiﬁcant diﬀerences versus food ingestion
on an empty stomach [8] were seen when long-acting
pramipexole was taken immediately after a hypercaloric
meal.
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Figure 2: Geometric mean of the pramipexole plasma-concentra-
tion time proﬁle at steady state after intake of pramipexole ER (dose
range: 0.375mg to 3.0mg/d) [6].
This study furthermore corroborated that pramipexole
plasma concentrations in healthy male subjects increased in
proportion to the doses of extended-release pramipexole, as
demonstrated in Figure 2. As this also holds true for the
immediate-release formula, patients can be switched to the
prolonged action formula for the night, whilst the daily dose
is maintained [6].
Based on the results of this study on relative bioavailabil-
ity, major approval studies used extended-release pramipex-
ole and immediate-release pramipexole in identical daily
doses, titration steps, and titration intervals. In a phase
III study on patients with early Parkinson’s disease,
plasma concentrations were determined before taking
the morning dose, and 1, 2, and 4 hours later after
a stable ﬁnal dose of pramipexole had been estab-
lished. Aided by population-centered pharmacokinetic pro-
cedures, this enabled the simulation of mean consecu-
tive time proﬁles of pramipexole plasma concentrations
in Parkinson patients as seen in Figure 3 [9]. It illus-
trates the desired 24 hours steady exposure in patients
after the application of the extended-release pramipexole
tablet.
All clinical studies conﬁrmed that matrix tablets are best
suited to make for the extended-release of pramipexole [10].
All developmental goals were attained, and, since October
2009,thisnewproducthasbeenapprovedinmanyEuropean
countries and the U.S.
In addition to the reliable immediate-release pramipex-
ole tablets, we can avail ourselves now of extended-release
pramipexole tablets. These are applied only once a day
to reach the daily requirement. Seven dosages have been
approved for the time being:4 Parkinson’s Disease
Table 1: Comparison of pharmacokinetic parameters in steady state after intake of Pramipexole IR 1.5mg t.i.d., Pramipexole ER 4.5mg q.d.
fasted, and Pramipexole ER 4.5mg q.d. after fat and protein-rich meal.
1.5mg Pramipexole
IR tablet t.i.d.
(n = 24)
4.5mg Pramipexole
ER tablet q.d. fasted
(n = 24)
4.5mg Pramipexole
ER tablet q.d. fed
(n = 24)
gMean gCV (%) gMean gCV (%) gMean gCV (%)
AUC0-24,ss
(ng·h/ml) 94.4 21.4 91.7 30.1 105 29.6
Cmax,ss
(ng/ml) 5.3 19.0 4.9 22.3 5.9 24.7
Cpre,ss (ng/ml) 2.8 27.7 2.7 31.1 2.6 58.4
gMean: geometric Mean; gCV: geometric variation coeﬃcient.
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Figure 3: simulated concentration time proﬁle of pramipexole ER
andpramipexoleIRatsteadystateinParkinsonpatientsafterintake
of pramipexole ER 4.5mg q.d. or pramipexole t.i.d.) in intervals of
8 hours (8-8-8) or diﬀerent intervals of 6 and 12 hours (6-6-12) [9].
0.375, 0.75, 1. 5, 2.25, 3, 3.75, and 4.5mg (S)-2-
amino-4,5,6,7-tetrahydro-6-propylamino-benzothiazole di-
hydrochloride monohydrate equivalent to 0.26, 0.52, 1.05,
1.57, 2.1, 2.62, or 3.15mg pramipexole base.
6.ClinicalData
Pramipexole is the most commonly prescribed dopamine
agonist worldwide and may well be considered the ref-
erence substance in the evaluation of new agents. Many
controlled studies have been published; the eﬃcacy and
the eﬃciency activity are well documented [11]. Extended-
release pramipexole (depot) was accordingly compared in
studies with immediate-release pramipexole. From clinical
viewpoints, the following aspects were focused on before the
introduction of the prolonged-action preparation:
(i) changefromimmediate-releasepramipexoletodepot
pramipexole,
(ii) eﬀectiveness of depot pramipexole in the early stage
of disease,
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Figure 4: Eﬃcacy of pramipexole IR versus pramipexole ER before
and after switch (week 4) comparing the change of mean UPDRS
score II + III [12].
(iii) eﬀectiveness of depot pramipexole in advanced
Parkinson’s disease.
7.SwitchingfromImmediate-Release
Pramipexoleto Extended-Release
Pramipexole
Switching a patient from immediate-release pramipexole to
extended-release pramipexole is preferably done overnight.
Rascol et al. [12] investigated to what extent that could be
done. In a double-blind study, 156 patients were switched
who had received invariably more than 1.05mg (base)
pramipexole for at least 4 weeks (on the average 1.9mg
(base) immediate-release pramipexole). Changes up to 15%
in the UPDRS (Uniﬁed Parkinson Disease Rating Scale)
II and III were rated noninferior. 84.5% were successfully
changed overnight (87 out of 103 patients). The proof on
noninferiority failed although extended-release pramipexole
turned out even better per UPDRS and CGI-I (Clinical
Global Impression Improvement), responder rate (87. 4
versus 78.8%) (Figure 4). There was no diﬀerence in side
eﬀects.Parkinson’s Disease 5
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Figure 5: Response rates of pramipexole IR versus pramipexole ER.
Comparison of the eﬃcacy parameters UPDRS II + II, CGI-I and
PGI at study endpoint (week 12, FAS) [13].
A second switch study was conducted by Mizuno et al.
in Japan [13], also making use of the overnight approach.
Thisdouble-blindstudywasrunfor12weeksin112patients,
followed by a 4-week open phase. The patients had a mean
3 years’ history of PD (2.9 and/or 3.1). The eﬃcacy was
assessed by UPDRS part II and III. Diﬀerences in UPDRS-
rating were irrelevant (immediate-release pramipexole 13.3,
extended-releasepramipexole13.6):thisalsopertainedtothe
dataofCGI-IandPGI-I(seeFigures4and5).Theswitchwas
successful in 83%. The rate of adverse eﬀects did not diﬀer.
In sum, the switch was uneventful in approximately 85%
ofthepatients.Theremainderdidnotcomplainaboutmajor
side eﬀects; they even indicated a better response under
immediate-release pramipexole.
8. Effectivenessof Extended-Release
Pramipexole in the Early Stage of Disease
The most valuable study to address this question was
conducted by Poewe et al. [14]. This work group scrutinized
539patientswhohadhadsymptomsforaveragely12months
and treated them with immediate-release pramipexole by 3-
arm design: depot pramipexole: placebo in a ratio of 2:2:1
for 26 weeks. The eﬀectiveness was checked upon after 18
weeks, the (noninferiority) after 33 weeks. UPDRS II and
III besides CGI-I (Clinical Global Impression Improvement)
and PGI-I (Patient Global Impression Improvement) served
as parameters. The two goals of the study were attained, that
is, proof of the superiority versus placebo in week 18 and
proof of the non-inferiority of extended-release pramipexole
in week 33 (−8.6 versus −8.8 scores). Relevant diﬀerences in
respect of CGI-I and PGI-I were not seen (46.1/33.3 versus
43.3/34.4%), The incidence and severity of side eﬀects did
not diﬀer either.
Another important interim analysis in this type of
patients is owed to Salin et al. [15]. In this 3-arm study,
101 patients were examined for 33 weeks. 84 patients were
evaluated at the end of the study, 35 of them being on
extended-release pramipexole, 31 under immediate-release
pramipexole and 18 under placebo. Changes of UPDRS II
and III were compared with week 18 to 33. The group taking
extended-release pramipexole scored higher by a change of
0.3 (−11.8 versus −11.5 points). The group treated with
immediate-release pramipexole presented with a change of
−11.9 points. The change in the placebo group amounted to
−4.2 points up to week 18 and −2.7 points to week 33. This
means that in both drug groups the eﬀect was maintained
between week 18 and 33 whereas a decline of 1.5 points in
was recorded in the placebo group.
Parallel data on response were also collected. PGI inter-
estingly enough revealed a slight superiority of the extended-
release formula compared to immediate-release pramipexole
in week 18 and 33 (45.7/42.9 versus 35.5/41.9%), evaluation
of CGI disclosed a superiority of the immediate-release
formula in week 18 and 33 (64.5/51.6 versus 46.9/40.6%).
Another analysis on extended-release pramipexole in the
early stage of PD was published by Hauser et al. [16].
Enrolled were 259 patients who had been ill for about
ay e a r .T h es t u d yw a sc a r r i e do nf o r1 8w e e k sw i t ha n
initial titration period of 7 weeks). This controlled double-
blindtrial(extended-releasepramipexole:immediate-release
pramipexole: placebo = 2:2:1) also focused on the eﬀect
by employing UPDRS II and III plus CGI-I and PGI-I.
An improvement by 7.5 points was found in the group
treated with immediate-release pramipexole (n = 99): the
group taking extended-release pramipexole (n = 99) scored
7.4 points and the placebo group (n = 42) 2.7 points.
Response rates were determined by GCI-I and PGI-I and
were indicative of improvements in week 18 and 33 for
extended-release pramipexole in 37/35.6%. The result was
48/23.8% under immediate-release pramipexole and 18/12%
under placebo.
The authors concluded that both pramipexole formulas
were safe and superior to placebo, aside from being well
tolerated. The eﬃcacy of extended-release pramipexole was
said to be similar to immediate-release pramipexole with
comparable adverse eﬀects.
9. Effectivenessof
Extended-ReleasePramipexolein
AdvancedParkinson’sDisease
The most signiﬁcant study on extended-release pramipexole
in the advanced stage of Parkinson’s disease was carried
out by Schapira et al. [17]. This examination included 517
patients, who had been diseased for about 6 years, treated
already by approximately 600mg levodopa. Used in a 3-
arm design were immediate-release pramipexole: extended-
release pramipexol: placebo in a ratio of 1:1:1. The supe-
riority of pramipexole was studied after 18 weeks by UPDRS
part II and III (Figure6)an db yo ﬀ periods. Theeﬀectiveness
was rechecked then 33 weeks later (n = 385). Extended-
release pramipexole proved superior after 18 weeks, reﬂected
by 4.9 points (−11.0 versus 6.1) in UPDRS and 0.7 (−2.1
versus 1.4) hours oﬀ time as opposed to placebo. There
were no relevant diﬀerences between immediate-release
pramipexole and extended-release pramipexole. The great
eﬀect of placebo was astonishing. Giddiness and vomiting
occurred less under extended-relapse pramipexole than
under immediate-release pramipexole.6 Parkinson’s Disease
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Figure 6: Eﬃcacy of Pramipexole ER in patients with advanced
Parkinson’s disease compared to pramipexole IR and placebo [17].
10. Consequences inClinicalPractice
The aforementioned studies conﬁrm preclinical data.
Immediate-release pramipexole and extended-release
pramipexole only vary in releasing the active agent from the
tablet. The substance itself is unchanged, meaning there is
an identical receptor proﬁle, identical eﬃcacy, and identical
receptor binding. The half-life of the agent is also the same,
but the continuous release from the depot tablet results in
an overall prolonged plasma half life. Any of the accepted
statements linked to immediate-release pramipexole also
apply to extended-release pramipexole-except for the daily
doses required. Extended-release pramipexole can be used
in both early and late Parkinson’s disease. A switch can take
place overnight, the ratio being 1:1, for example, immediate-
release pramipexole 3 × 0.7mg (base) are consistent with
2.1mg extended-release pramipexole. In most cases, the
patient is not going to be aﬀected by this switch. More
eﬃcaciousness, increased dyskinesias or undesired eﬀects
are not to be expected. In a few cases, the eﬀect may be
less, which would require a dose adjustment. Some patients
appreciate the stimulating eﬀect of immediate-release
pramipexole with a rapid aﬄux and higher peak and for this
reason, they prefer fast-release pramipexole. So far, there
have been no insights regarding any increased individual
side eﬀect owing to the use of extended-release pramipexole.
Reduction of plasma peaks might even result in decreased
side eﬀects.
The once daily application constitutes the essential and
cardinal advantage of the extended-release formula. This is
deﬁnitely going to improve compliance, and to ameliorate
disease control. The argument that the patient gets levodopa
3 times a day anyways does not hold, since levodopa is taken
food dependent (competitive action of alimentary amino
acids to levodopa during its resorption [18]); a 3x daily
scheme can well be turned into a 6x daily one. Extended-
release pramipexole can also be split into 2 administrations
if clinically applicable albeit this is not provided for in the
approval.
Since the introduction of extended-release pramipex-
ole, and in consideration of pharmacologic and clinical
aspects, it has been recommended putting the patient on
extended-releasepramipexoleinanewapproach.Allpatients
who have been under immediate-release pramipexole may
furthermore be switched to extended-release pramipex-
ole overnight. The inauguration of extended release-
pramipexole is to be regarded as another important option
in the drug treatment of Parkinson’s disease.
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